Lenox Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-162
Closed -$5K 769
2021
Q1
$5K Sell
162
-162
-50% -$5.77K ﹤0.01% 508
2020
Q4
$11K Buy
+324
New +$11.2K ﹤0.01% 414
2020
Q2
Sell
-298
Closed -$9K 731
2020
Q1
$9K Buy
+298
New +$8.87K ﹤0.01% 358
2019
Q4
Sell
-460
Closed -$12K 791
2019
Q3
$12K Hold
460
﹤0.01% 345
2019
Q2
$12K Hold
460
﹤0.01% 267
2019
Q1
$12K Hold
460
﹤0.01% 256
2018
Q4
$11K Hold
460
﹤0.01% 243
2018
Q3
$11K Buy
+460
New +$11.2K ﹤0.01% 273
2018
Q2
Sell
-378
Closed -$9K 613
2018
Q1
$9K Buy
+378
New +$9.92K ﹤0.01% 370
2017
Q4
Sell
-182
Closed -$4K 433
2017
Q3
$4K Buy
+182
New +$4.11K ﹤0.01% 89
2017
Q2
Sell
-1,150
Closed -$20K 115
2017
Q1
$20K Hold
1,150
0.01% 64
2016
Q4
$21K Sell
1,150
-160
-12% -$2.9K 0.01% 80
2016
Q3
$27K Buy
1,310
+160
+14% +$3.97K 0.01% 119
2016
Q2
$31K Hold
1,150
0.01% 111
2016
Q1
$31K Sell
1,150
-54
-4% -$1.45K 0.01% 114
2015
Q4
$35K Sell
1,204
-694
-37% -$19.2K 0.01% 107
2015
Q3
$51K Buy
1,898
+748
+65% +$21.2K 0.02% 85
2015
Q2
$31K Hold
1,150
0.01% 81
2015
Q1
$31K Hold
1,150
0.01% 96
2014
Q4
$24K Buy
+1,150
New +$25.7K 0.01% 117

Other funds holding NVO

Lenox Wealth Advisors's NVO Position: Q2 2021 in Review

Lenox Wealth Advisors sold out of Novo Nordisk (NVO) in Q2 2021, closing a stake of 162 shares — an estimated $5K sold.

Lenox Wealth Advisors first reported a position in NVO in Q4 2014 and held it in 20 quarters. The position peaked at $51K in Q3 2015. 736 funds tracked by Wall St. Rank hold NVO as of Q2 2021.

  • Lenox Wealth Advisors reported no remaining Novo Nordisk position as of Q2 2021 after selling out during the quarter.
  • Lenox Wealth Advisors sold 162 Novo Nordisk shares in Q2 2021, an estimated $5K.
  • Lenox Wealth Advisors first reported a position in Novo Nordisk in Q4 2014 and held it in 20 quarters.
  • Lenox Wealth Advisors's Novo Nordisk position peaked at $51K in Q3 2015.
  • 736 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2021.

Based on Lenox Wealth Advisors's 13F filing for Q2 2021, filed 8 Jul 2021.